Tau, the protein that has displaced amyloid as the central target in Alzheimer's drug development, appears to damage brain cells by infiltrating their energy-producing machinery and running it backward.
A team led by Stanford Medicine researchers reports in Neuron that tau can enter mitochondria and drive electrons in the opposite direction of their normal path, a reversal that generates reactive oxygen species, cellular stress and inflammation.
The work matters less for what it adds to the list of things tau does than for what it suggests about where to intervene. Blocking the reversal reduced neurodegeneration and improved learning and memory in flies and mice.
The Field's Shift from Amyloid to Tau
For decades, amyloid beta plaques dominated Alzheimer's research and drug development. That focus produced approved therapies, but the clinical benefit has been modest relative to the investment and the expectations.
Tau gained ground for a straightforward reason: it tracks the disease better. Tau pathology correlates more closely with cognitive decline and with the pattern and timing of neuron loss than amyloid plaque burden does. Patients can carry substantial amyloid with preserved cognition, whereas tau spread through the brain follows the progression of symptoms.
Tau also appears in conditions where amyloid does not, including frontotemporal dementia and other disorders grouped as tauopathies. That range means a tau-directed therapy could in principle address several diseases rather than one, which is part of the commercial and scientific appeal.
The protein's normal job is structural. Tau binds and stabilizes microtubules, the internal scaffolding that maintains a neuron's shape and along which cargo is transported. Chemical modifications called phosphate groups regulate that binding, and hyperphosphorylated tau detaches, misfolds, and aggregates into the tangles that define the pathology.
What has remained unresolved is whether tau actively drives neurodegeneration or is largely a marker of it. Tau-targeting therapies have seen limited success so far, which sharpened that question rather than settling it.
The Mechanism the Researchers Describe
Mitochondria generate cellular energy through the electron transport chain, a sequence in which electrons pass between protein complexes in a fixed direction, ultimately producing ATP.
Reverse electron transport is a recognized phenomenon in which electrons travel backward through part of that chain. It is a potent generator of reactive oxygen species.
The specific finding is that only tau molecules that have undergone particular phosphorylation events can enter mitochondria. Once inside, they bind to NDUFS3, a subunit of complex I, and warp its shape. That jams the conveyor belt and sends electrons backward. Reactive oxygen species accumulate, the NAD+ to NADH ratio falls, and the process is amplified by aging or stress, producing inflammatory signaling and cellular damage.
"This is the first demonstration of exactly what tau does inside mitochondria," said Bingwei Lu, a Stanford professor of pathology and senior author. "Our discovery of a whole new mechanism driving tauopathies renders these disorders amenable to new therapeutic interventions."
That framing offers something the tangle-focused model does not: a specific, measurable cellular process linking tau presence to neuron damage. Tangles are visible and easy to count, which made them the focus for decades, but counting them never explained how a neuron actually dies. The authors report the damage occurs independently of tangle formation.
The work spanned fruit flies, mice, neurons derived from human stem cells and human brain tissue. Depleting tau genetically or pharmacologically halted the reversal and conferred resilience to stress.
The Complication That the Drug Candidate May Resolve
Broad tau reduction is the strategy most tau therapies pursue. Another line of research complicates it.
MedicalDaily reported last month on work concluding that controlled, normal-level tau phosphorylation is essential for organizing the brain's memory-encoding cells into durable memories. If normal tau function is required for memory, then indiscriminately lowering tau throughout the brain risks removing something necessary alongside something harmful.
The current work suggests a way around that. The team tested an experimental compound called CPT, which prevents hyperphosphorylated tau from binding NDUFS3 and blocks reverse electron transport without impairing normal forward electron flow. In tauopathy mice with severe cognitive deficits, an extended CPT regimen inhibited reverse electron transport in brain mitochondria, improved performance across a range of behavioral tests, and prevented nerve cell inflammation along with markers of neurodegeneration including reduced cortical thickness and brain volume.
That is selectivity rather than blanket suppression, which is what the memory findings argue for. It is also a compound tested in animals, not a drug.
Tau-lowering therapies are meanwhile in advanced development. Biogen's diranersen, formerly BIIB080, is an antisense oligonucleotide that reduces tau production. Its phase 2 CELIA trial reported in May that it did not meet its primary endpoint, which assessed dose response, but produced robust reductions in tau pathology across all doses and slowing of clinical decline, strongest at the lowest dose. At that dose, participants showed 26% less decline on the Clinical Dementia Rating-Sum of Boxes over 18 months compared with placebo. Biogen is advancing the drug to phase 3.
Those results are meaningful, and they come from a single phase 2 trial in early-stage patients, which is not where most of the disease burden sits. Most people receive an Alzheimer's diagnosis well after the point that trial enrolled, and whether tau reduction helps at that stage has not been established.
The Practical Distance from Patients
This is mechanistic laboratory research. It identifies a process and a candidate compound, not a treatment, and no approved therapy follows directly from it.
A nearer useful application may be in trial design. If reverse electron transport is the damaging step, markers of mitochondrial oxidative stress could serve as early readouts, potentially indicating whether a tau-targeting drug is doing what it should before cognitive endpoints could show it.
For patients and families, nothing changes today. Approved Alzheimer's treatments remain what they were, and no supplement or intervention marketed for mitochondrial support or tau reduction has been shown to affect the disease.
What does have evidence is unglamorous: managing blood pressure, treating hearing loss, staying physically active, maintaining social engagement and controlling diabetes are all associated with reduced dementia risk. Those have better support than anything derived from tau biology so far.
Anyone concerned about memory changes should be evaluated rather than waiting, since some causes of cognitive symptoms, including thyroid disease, vitamin deficiency, medication effects, depression, and sleep apnea, are treatable and reversible. MedicalDaily has covered how long a mechanism takes to become a medicine in other fields.
Key Questions Answered
What did the researchers find? That phosphorylated tau can enter mitochondria, bind the complex I subunit NDUFS3, warp its shape, and drive electrons backward through the electron transport chain, generating reactive oxygen species, cellular stress, and inflammation.
Why has tau replaced amyloid as the main target? Tau pathology tracks cognitive decline and neuron loss more closely than amyloid plaque burden does. People can carry substantial amyloid with preserved cognition, while tau spread follows symptom progression.
What does tau normally do? It binds and stabilizes microtubules, the internal scaffolding that maintains a neuron's shape and supports transport within the cell. Phosphate groups regulate that binding.
Does this mean lowering tau is the right strategy? Not straightforwardly. Separate research indicates normal-level tau phosphorylation is necessary for memory formation. The experimental compound tested here blocks the specific harmful interaction without disrupting normal electron flow, which is a more selective approach.
Have tau drugs worked in trials? Results are early and mixed. Biogen's diranersen missed its primary endpoint in the phase 2 CELIA trial but reduced tau pathology across doses and showed 26% less decline on one cognitive scale at the lowest dose. It is advancing to phase 3.
Is a treatment available from this work? No. This is mechanistic laboratory research in flies, mice, stem cell-derived neurons, and human tissue. The compound tested is experimental.
What actually reduces dementia risk now? Managing blood pressure, treating hearing loss, staying physically active, maintaining social engagement and controlling diabetes all have supporting evidence. Memory changes should be evaluated, since some causes are treatable and reversible.
